Companies:
53,646
Total Market Cap:
170828112140399.80
Global Rank
#50011
Country Rank
#6045
Market Cap
1.2 M
Price
0.233
Change (%)
3.70%
Volume
4.43 M
Jaguar Health's latest marketcap:
1.2 M
As of 09/17/2026, Jaguar Health's market capitalization has reached $1.2 M. According to our data, Jaguar Health is the 50011th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.2 M |
| Revenue (ttm) | 27.82 M |
| Net Income (ttm) | -52,420,000 |
| Shares Out | 5.17 M |
| EPS (ttm) | -155.88 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/19/2026 |
Market Cap Chart
Data Updated: 09/17/2026
Jaguar Health's yearly market capitalization.
Jaguar Health has seen its market value drop from $5.41 M to $1.2 M since 2018, representing a total decrease of 77.75% and an annual compound decline rate (CAGR) of 17.70%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 09/17/2026 | $1.2 M | -72.52% | 50011 |
| 12/31/2025 | $4.22 M | -64.54% | 41583 |
| 12/31/2024 | $11.92 M | 55.19% | 37124 |
| 12/29/2023 | $7.68 M | -40.94% | 38174 |
| 12/30/2022 | $13 M | -71.13% | 34772 |
| 12/31/2021 | $45.04 M | -47.35% | 27817 |
| 12/31/2020 | $85.54 M | 619.17% | 21507 |
| 12/31/2019 | $11.89 M | 119.91% | n/a |
| 12/31/2018 | $5.41 M | n/a |
Company Profile
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company specializing in plant-based prescription medicines for gastrointestinal distress, particularly chronic and debilitating diarrhea in humans and animals.
Business Segments
- Human Health: Focuses on developing and commercializing prescription and non-prescription products for human use.
- Animal Health: Dedicated to products for companion and production animals.
Key Products
- Mytesi: An anti-secretory antidiarrheal drug for non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Canalevia-CA1: A prescription drug for chemotherapy-induced diarrhea in dogs.
Pipeline Developments
- Crofelemer: In Phase 3 clinical trials for diarrhea in adult cancer patients and rare/orphan disease indications, including short bowel syndrome and congenital diarrheal disorders.
- NP-300: A second-generation antidiarrheal drug for moderate-to-severe diarrhea.
Headquarters: San Francisco, California
Frequently Asked Questions
-
What is Jaguar Health's (JAGX) current market cap?As of 09/17/2026, Jaguar Health (including the parent company, if applicable) has an estimated market capitalization of $1.2 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Jaguar Health (JAGX) rank globally by market cap?Jaguar Health global market capitalization ranking is approximately 50011 as of 09/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.